Neurogene Inc.
NGNE
$17.20
$0.3952.35%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.50% | 2.70% | 21.59% | 34.20% | -- |
| Total Depreciation and Amortization | -2.90% | 8.42% | 5.95% | 3.03% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -632.30% | -613.78% | -780.49% | -873.06% | -- |
| Change in Net Operating Assets | -1,109.10% | -3,872.87% | -145.85% | -49.28% | -- |
| Cash from Operations | -57.02% | -50.53% | -17.91% | 2.65% | -- |
| Capital Expenditure | -97.59% | -120.72% | 71.55% | 85.61% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 867.47% | 9,730.33% | 4,530.36% | 1,249.64% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -113.64% | -275.00% | -483.33% | -2,800.00% | -- |
| Issuance of Common Stock | 452.56% | 448.22% | 278.45% | 130.14% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4,544.77% | 85,401.00% | -- | -- | -- |
| Cash from Financing | 5,049.72% | 125,024.64% | 157.07% | 39.01% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 145.72% | 218.47% | 546.89% | 481.14% | -- |
